Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Sorrento Therapeutics Acquires Sofusa Platform from Kimberly-Clark 17
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 18
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 19
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 20
Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 21
Venture Financing 22
Celularity Raises USD250 Million in Venture Financing 22
Celularity Raises Funds through Series A Financing 24
Scilex Pharma Raises USD0.5 Million in Financing 25
Globavir Biosciences Secures USD4 Million in Venture Funding 26
Scilex Pharma Raises US$5 Million In Venture Financing 27
Partnerships 28
Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 28
Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 29
Sorrento Therapeutics to Form Joint Venture with CHA Biotech 31
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 32
Sorrento Therapeutics Forms Joint Venture with Yuhan 33
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 34
Sorrento Therapeutics forms Joint Venture with City of Hope 35
Sorrento Therapeutics and NantBioscience Form Joint Venture 36
Advaxis Enters into Research Agreement with Sorrento Therapeutics 37
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 38
NantWorks to Form Joint Venture with Sorrento Therapeutics 39
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 40
Licensing Agreements 41
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 41
Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 42
Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 43
Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 44
NantWorks Enters into Licensing Agreement with Sorrento Therapeutics 45
NantCell Enters into Licensing Agreement with Sorrento Therapeutics 46
Sorrento Therapeutics Enters into Licensing Agreement with Lee’s Pharma for Anti-PD-L1 Antibody 47
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48
Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 49
Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 50
Equity Offering 51
Sorrento Therapeutics Files Registration Statement to Raise up to USD269 Million in Public Offering of Shares 51
Sorrento Therapeutics to Raise up to USD100 Million in Public Offering of Shares 52
Sorrento Therapeutics Plans to Raise Funds through Private Placement of Shares 53
Sorrento Therapeutics to Raise Funds through Public Offering of Shares 54
Sorrento Therapeutics Raises USD47.3 Million in Public Offering of Shares 55
Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 57
Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 58
Sorrento Therapeutics Raises USD28.8 million in Public Offering of Shares 60
Scilex Pharma Raises USD5 Million in Private Placement Of Shares And Warrants 62
Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million 63
Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million 65
Debt Offering 66
Scilex Pharma Raises USD140 Million in Private Placement of Notes Due 2026 66
Sorrento Therapeutics to Raise USD120.5 Million in Private Placement of 5% Notes 67
Sorrento Therapeutics Raises USD50 Million in Private Placement of 5% Notes and Warrants 68
Sorrento Therapeutics Raises USD1.9 Million in Public Offering of Notes 69
Asset Transactions 70
Celularity Acquires Assets from TNK Therapeutics 70
Acquisition 71
TNK Therapeutics Acquires Virttu Biologics 71
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 72
TNK Therapeutics Acquires Two Biotechnology Companies 73
NantPharma Acquires IgDraSol from Sorrento Therapeutics 74
Itochu Chemical Frontier Invests in Scilex Pharma 75
NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 76
Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million 77
Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 78
Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million 79
Sorrento Therapeutics Inc – Key Competitors 81
Sorrento Therapeutics Inc – Key Employees 82
Sorrento Therapeutics Inc – Locations And Subsidiaries 83
Head Office 83
Other Locations & Subsidiaries 83
Joint Venture 84
Recent Developments 85
Strategy And Business Planning 85
May 04, 2017: Sorrento Therapeutics Announces the Completion of GMP Manufacturing Plant in Suzhou, China to Support its Growing Antibody-Drug Conjugate (ADC) Pipeline and Service Business 85
Corporate Communications 86
Mar 19, 2018: Sorrento Therapeutics Welcomes Jiong Shao as Chief Financial Officer and Reaffirms Intent to Seek Nasdaq/HKSE Dual Listing in 2018 86
Oct 02, 2017: Sorrento Therapeutics Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors 87
Legal and Regulatory 88
Jun 14, 2017: Sorrento Therapeutics Announces Dismissal Of Lawsuits 88
Product News 89
Aug 21, 2017: Celularity Accelerates Breakthrough Placental Discovery & Therapeutic Platform 89
06/14/2017: Sorrento Therapeutics’ Pain Subsidiary, SCILEX Pharmaceuticals, Announces Positive Data from Head to Head Adhesion Study with its Lead Product, ZTlido 90
02/28/2018: Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for PHN Pain 91
01/09/2017: Sorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido 93
Product Approvals 94
Nov 14, 2017: Scilex Pharmaceuticals, Sorrento Therapeutics Subsidiary, Files Marketing Authorization Application In The European Union For ZTlido 94
Aug 29, 2017: Sorrento Therapeutics Submits NDA For ZTlido Next-Generation Lidocaine Patch 95
Jun 29, 2017: Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain 96
Clinical Trials 97
Sep 07, 2018: Scilex Presents ZTlido Data on Superior Adhesion over Lidocaine Patch Formulation 97
Feb 05, 2018: Sorrento’s and Yuhan’s Joint Venture, ImmuneOncia, receives Approval to begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea 99
Jan 29, 2018: China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal Antibody 100
Other Significant Developments 101
Mar 28, 2018: Sorrento Therapeutics Chairman/CEO update to stockholders 101
Feb 05, 2018: Sorrento Therapeutics Chairman/CEO letter to stockholders 102
Appendix 104
Methodology 104
About GlobalData 104
Contact Us 104
Disclaimer 104
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sorrento Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Sorrento Therapeutics Acquires Sofusa Platform from Kimberly-Clark 17
Sorrento Therapeutics Acquires Rights to Cynviloq from Samyang Biopharma 18
Sorrento Therapeutics Acquires Rights To Cynviloq From Samyang Biopharma 19
Sorrento Therapeutics And IgDraSol Acquire Distribution Rights Of Cynviloq From Samyang Biopharma 20
Sorrento Therapeutics Acquires Rights To Produce Recombinant Intravenous Immunoglobulins 21
Celularity Raises USD250 Million in Venture Financing 22
Celularity Raises Funds through Series A Financing 24
Scilex Pharma Raises USD0.5 Million in Financing 25
Globavir Biosciences Secures USD4 Million in Venture Funding 26
Scilex Pharma Raises US$5 Million In Venture Financing 27
Sorrento Therapeutics and TNK Therapeutics Enters into Licensing Agreement with CytoLumina Technologies and FetoLumina Technologies 28
Sorrento Therapeutics, Celgene, United Therapeutics and Human Longevity Form Joint Venture 29
Sorrento Therapeutics to Form Joint Venture with CHA Biotech 31
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 32
Sorrento Therapeutics Forms Joint Venture with Yuhan 33
Sorrento Therapeutics Enters into Partnership with Karolinska Institutet 34
Sorrento Therapeutics forms Joint Venture with City of Hope 35
Sorrento Therapeutics and NantBioscience Form Joint Venture 36
Advaxis Enters into Research Agreement with Sorrento Therapeutics 37
Sorrento Therapeutics Enters into Collaboration Agreement with Conkwest 38
NantWorks to Form Joint Venture with Sorrento Therapeutics 39
Sorrento Therapeutics Enters into Co-Development Agreement with Morphotek 40
Les Laboratoires Servier Enters into Licensing Agreement with Sorrento Therapeutics 41
Sorrento Therapeutics Enters into Licensing Agreement with City of Hope 42
Sorrento Therapeutics Enters into Licensing Agreement with Mabtech 43
Sorrento Therapeutics Enters into Licensing Agreement with Globavir Biosciences 44
NantWorks Enters into Licensing Agreement with Sorrento Therapeutics 45
NantCell Enters into Licensing Agreement with Sorrento Therapeutics 46
Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 47
Sorrento Therapeutics Enters Into Licensing Agreement With Lonza For GS Xceed Gene Expression System 48
Sorrento Therapeutics Enters Into Licensing Agreement With Scripps Research Institute 49
Sorrento Therapeutics Enters Into Option For Licensing Agreement With B.G. Negev Technologies and Applications For HCV Antibody Clones 50
Sorrento Therapeutics Files Registration Statement to Raise up to USD269 Million in Public Offering of Shares 51
Sorrento Therapeutics to Raise up to USD100 Million in Public Offering of Shares 52
Sorrento Therapeutics Plans to Raise Funds through Private Placement of Shares 53
Sorrento Therapeutics to Raise Funds through Public Offering of Shares 54
Sorrento Therapeutics Raises USD47.3 Million in Public Offering of Shares 55
Sorrento Therapeutics Raises USD140 Million in Private Placement of Shares and Warrants 57
Sorrento Therapeutics Raises USD10 Million in Private Placement of Shares and Warrants 58
Sorrento Therapeutics Raises USD28.8 million in Public Offering of Shares 60
Scilex Pharma Raises USD5 Million in Private Placement Of Shares And Warrants 62
Sorrento Therapeutics Completes Public Offering Of Shares For US$34.6 Million 63
Sorrento Therapeutics Files Registration Statement For Public Offering Of Securities For Up To US$100 Million 65
Scilex Pharma Raises USD140 Million in Private Placement of Notes Due 2026 66
Sorrento Therapeutics to Raise USD120.5 Million in Private Placement of 5% Notes 67
Sorrento Therapeutics Raises USD50 Million in Private Placement of 5% Notes and Warrants 68
Sorrento Therapeutics Raises USD1.9 Million in Public Offering of Notes 69
Celularity Acquires Assets from TNK Therapeutics 70
TNK Therapeutics Acquires Virttu Biologics 71
Sorrento Therapeutics Acquires 72% Stake in Scilex Pharma for USD47.6 Million 72
TNK Therapeutics Acquires Two Biotechnology Companies 73
NantPharma Acquires IgDraSol from Sorrento Therapeutics 74
Itochu Chemical Frontier Invests in Scilex Pharma 75
NantWorks to Acquire 19.9% Stake in Sorrento Therapeutics for USD41.7 Million 76
Sorrento Therapeutics Completes Acquisition Of Concortis Biosystems For Up To US$12 Million 77
Sorrento Acquires Sherrington, Chronic Pain Therapies Provider 78
Sorrento Therapeutics Completes Acquisition Of IgDraSol For US$28.2 Million 79
Sorrento Therapeutics Inc, Key Competitors 81
Sorrento Therapeutics Inc, Key Employees 82
Sorrento Therapeutics Inc, Subsidiaries 83
Sorrento Therapeutics Inc, Joint Venture 84
List of Figures
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sorrento Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sorrento Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12